Ivermectin - A useful treatment for COVID-19 coronavirus? Some discussion and studies...

[sharon sanders]

bump this

[bertrand789]

Emily

https://scholar.google.com/scholar?oi=gsb95&q=Mice%20with%20disrupted%20P-glycoprotein%20genes&lookup=0&hl=fr

https://scholar.google.com/scholar?hl=fr&as_sdt=0%2C5&as_ylo=2020&q=Mice+with+disrupted+P-glycoprotein+genes%2Ccovid&btnG=

[Emily]

Good to know there is a test for dogs. I had a herding breed dog in the past so that's why I knew about this. Fortunately I didn't find out the hard way. He also had the atypical reaction to acepromazine. That was scary.
The genetics in humans should be rarer since we're more diverse right now.

[bertrand789]

I couldn't imagine you being silent for long. There were also cases on cattle which expressed a clinical rabies, which makes you want ... In fact, it was considered, as a line to be eliminated ...

There is a genetic susceptibility test for dogs: https://vcpl.vetmed.wsu.edu/

https://www.ejcancer.com/article/0959-8049(96)00063-9/pdf

Is it not the same for humans?

tell us about this glyco protein and the consequences not only for this molecule ...

[Emily]

Ivermectin can be very toxic to some breeds or mixed breed dogs.

https://www.petmd.com/dog/conditions...ectin_toxicity

https://onlinelibrary.wiley.com/doi/...2002.tb01611.x


The genetics of susceptible collies and a possible similar condition in rare cases of human toxicity discussed here:
http://www.academia.edu/download/391...c639000000.pdf
(Or try this to get the PDF) https://scholar.google.com/scholar?h...0000.pdf&btnG=
Ivermectin 20 years on: maturation of a wonder drug
TG Geary - Trends in parasitology, 2005

Here is Dr. Kory's group's website.

https://covid19criticalcare.com/

Dr. Been talks about ivermectin here:

https://www.youtube.com/watch?v=17_U4RPOvqE

[Vibrant62]

This medic has made a highly impassioned plea at a US senate hearing for his working groups data to be examined here - he certainly sounds sincere, and as he said, his working group has collectively authored over 2000 peer reviewed and published studies in their careers to date, so they do have both reputations and experience.

https://www.youtube.com/watch?v=Tq8S...P34PLyWa2iSR1c

The document he is referring to (I think) is presented here and contains an overview of key findings of a number of studies including RCTs) https://osf.io/wx3zn/

The referenced studies have issues - many are pre-print but they are (mostly) randomised controlled trials of a reasonable size. At the very least this looks like it warrants a definitive international RCT, and let us hope that a major journal expedites peer review of the paper his group has authored. The problem here is that as Ivermectin is a generic, no large pharmaceutical company will fund it or push for it (the opposite is much more likely). As such, any such drive will have to be put in place by medics themselves and/or driven by media and press coverage - unless perhaps a very large generic company might be prepared to get behind this, if one of a big enough size exists? The UK does not even have an EUA in place so any move towards larger trials would have to be led from the top downwards e.g. EMEA, the WHO or regulatory authorities who are not unduly influenced by big Pharma. Even research centres are particularly sensitive to influence as in normal times it is Pharma who funds their research, but in these exceptional times I would hope this is not the case.

I am most concerned that there is no Plan B - if the vaccine runs into major issues, or the virus evolves away from the vaccine i.e no longer provokes sterilising antibodies, we will have problems for some years and even IF the vaccine companies were able to manufacture the quantities needed in the timescales needed (it will be at least 2022/2023 before current demand is met), we will all be back to square one whilst they address the problems.

There look to be some promising treatments for the most severe hospitalised patients but as of now there is nothing for GPs / primary care to give to patients to help them unless cases are so severe they require hospitalisation. As the threat and impacts of long covid become increasingly apparent this is critically important for health and economies to get on top of, and novel and expensive therapies will not be affordable or producible at sufficient scale, even in the richest countries e.g.monoclonal antibodies, vaccines and remdesivir (which I would argue has minimal benefit and high toxicity). For these reasons alone it has to be worth some time, money and effort to determine if these findings and data on ivermectin for the prophylaxis and post exposure prophylaxis stand the test of larger scale international study/ studies.

At best, it could help to bridge the gap between widespread vaccine availability for entire populations and save lives and reduce the numbers with long covid, at worst it could act as insurance in the event of a significant vaccine escape, or some other major issue emerging with the vaccines e.g. ADE or other longer term side effects - the occurrence of any of these would set the world back at least a year if not longer in its road to economic recovery.

[sharon sanders]

Since I live in Florida all of my dogs since 1984 have been on heart worm preventative their entire lives. I believe the medicine prescribed has been mostly ivermectin. One small breed dog lived until 17 years old. A large breed dog died at 12. Another large breed died in her teens of old age - I forget her exact age at death. I have two dogs now both on heartworm preventative. No problems that I know of. These are not humans, but they are mammals.

(they think they are humans, however)

[kiwibird]

https://twitter.com/Covid19Critical/status/1335952794336038913/photo/1

"Ivermectin is effectively a “miracle drug” against COVID-19. The data shows that it prevents transmission & progression of illness in nearly all who take it." Dr. Pierre Kory testifies to the Senate Committee on Homeland Security & Governmental Affairs tomorrow in D.C

And a twitter link summarising - https://c19ivermectin.com/

[sharon sanders]

Thanks Vibrant62. I copied your two posts from the discussion thread to start this one. Thanks tetano for all of your work in the Scientific Library. I listed a few of the Ivermectin studies above.

Ivermectin? I have no idea if it works but we should discuss it. Hopefully I do not get bashed like I did when I opened a thread on hydroxychloroquine. We investigate everything here. Pros and cons. There is an informative value in this pursuit.

We do not do cancel culture on this site.

[sharon sanders]

I found this recent review on ivermectin data, which looks interesting and appears to have some very positive data behind it, albeit a lot of it is pre full publication.. However, I suspect that as it is a generic and not licensed or produced in some countries e.g. the UK for any indication that this may get overlooked as it will be of little interest to the mainstream Pharma sector.

See https://covid19criticalcare.com/wp-c...IN-Summary.pdf

There needs to be some high quality trials undertaken very rapidly to take a proper look at this compound, but I am not able to determine if there are any of a suitable design, size or quality underway. What do we think? We do still need compounds that will fill the gap around vaccines (limitations in production capacity and roll outs), especially if (as per gsgs' post above) we get a rapid vaccine escape.

Please see:


J Control Release . Ivermectin: An award-winning drug with antiviral expectations against COVID-19

Avicenna J Med Biotechnol . Effective Anti-SARS-CoV-2 RNA Dependent RNA Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin, and Baloxavir Marboxil

J Cell Physiol . Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment

Ann Clin Microbiol Antimicrob Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19

[Vibrant62]

Safety / ADR profile here when used for current indications https://www.medicalnewstoday.com/art...other-warnings

[Vibrant62]

I found this recent review on ivermectin data, which looks interesting and appears to have some very positive data behind it, albeit a lot of it is pre full publication.. However, I suspect that as it is a generic and not licensed or produced in some countries e.g. the UK for any indication that this may get overlooked as it will be of little interest to the mainstream Pharma sector.

See https://covid19criticalcare.com/wp-c...IN-Summary.pdf

There needs to be some high quality trials undertaken very rapidly to take a proper look at this compound, but I am not able to determine if there are any of a suitable design, size or quality underway. What do we think? We do still need compounds that will fill the gap around vaccines (limitations in production capacity and roll outs), especially if (as per gsgs' post above) we get a rapid vaccine escape.